Skip to main content
. Author manuscript; available in PMC: 2017 Aug 30.
Published in final edited form as: Med Oncol. 2017 Jan 30;34(3):33. doi: 10.1007/s12032-017-0889-2

Table 1.

DDX3 expression and other clinicopathological characteristics in breast cancer in BRCA1 or BRCA2 germline mutation carriers as compared to sporadic breast cancers

Sporadic BRCA1 P value BRCA2 P value
DDX3 expression [n (%)] 0.337a 0.624a
 Absent 3 (1) 0 0
 Weak 34 (13) 19 (18) 5 (17)
 Moderate 148 (56) 59 (57) 18 (62)
 Strong 80 (30) 25 (24) 6 (21)
Age [median (IQR)] 58 (18) 40 (11.5) <0.001b 50 (11) <0.001b
B&R grade [n (%)] <0.001 0.014a
 1 45 (17) 2 (2) 0
 2 99 (37) 15 (16) 8 (31)
 3 121 (46) 78 (82) 18 (69)
 Missing 0 0 1
MAI [median (IQR)] 12 (18) 25 (25) <0.001b 17 (13) 0.110a
 Missing 0 13 3
Histological type [n (%)] 0.064 0.667a
 Invasive ductal carcinoma 225 (85) 80 (84) 25 (93)
 Invasive lobular carcinoma 24 (9) 4 (4) 2 (7)
 Other 15 (6) 11 (12) 0
 Missing 1 8 2
Tumor size (cm) [median (IQR)] 2 (2) 2 (2) 0.924b 1 (1) 0.029b
 Missing 22 26 6
ER [n (%)] <0.001 1
 Negative 50 (19) 76 (77) 5 (19)
 Positive 215 (81) 23 (23) 22 (81)
 Missing 0 4 2
PR [n (%)] <0.001 0.171
 Negative 87 (33) 81 (83) 13 (48)
 Positive 177 (67) 17 (17) 14 (52)
 Missing 1 5 2
HER2 [n (%)] 0.828 1a
 Negative 243 (92) 94 (93) 26 (93)
 Positive 22 (8) 7 (7) 2 (7)
 Missing 0 2 1
Molecular classification [n (%)] <0.001a 0.897a
 Luminal A 208 (78) 20 (21) 21 (81)
 Luminal B 12 (5) 4 (4) 1 (4)
 HER2 overexpressing 10 (4) 4 (4) 0
 Basal-like 35 (13) 67 (71) 4 (15)
 Unclassified 0 0 0
 Missing

P value calculated by Chi-square test unless otherwise indicated

n number, B&R Bloom and Richardson, MAI mitotic activity index, IQR interquartile range

a

Fisher exact test

b

Mann–Whitney U test